
Keywords: ALK; anaplastic lymphoma kinase; CNS; central nervous system; EGFR; epidermal growth factor receptor; FDA; food and drug administration; GCN; gene copy number; HGF; hepatocyte growth factor; IC50; half inhibitory concentration; IHC; immunohistochemistry;